Volume 17, Issue 60 (Oct 2007)
J Mazandaran Univ Med Sci 2007, 17(60): 6-13 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zarrabi ahrabi N, Behradkia P, Shafiei M, Joharidaha F, Najafi R, Montaser Kohestani S et al . Production and Quality Control of Technetium-99m Radiolabeled Monoclonal Antibody . J Mazandaran Univ Med Sci 2007; 17 (60) :6-13
URL: http://jmums.mazums.ac.ir/article-1-245-en.html
URL: http://jmums.mazums.ac.ir/article-1-245-en.html
N Zarrabi ahrabi 
, P Behradkia , M Shafiei , F Joharidaha , R Najafi , SH Montaser Kohestani , M.H Babaee
, P Behradkia , M Shafiei , F Joharidaha , R Najafi , SH Montaser Kohestani , M.H Babaee
Abstract: (24296 Views)
Background and purpose: Binding a monoclonal antibody to tumor associated antigens is an effective method for cancer therapy because these agents can specifically target malignant cells. In fact, monoclonal antibodies are effective agents for diagnosis, grading and treatment of different kinds of cancers. In this research, a new monoclonal antibody against colon cancer cells was prepared and radiolabeling with technetium-99m evaluated.
Materials and Methods: This research was done in three parts: preparation of hybridoma cell against colon cancer cell line (HT29), production of monoclonal antibody, determination of its characterizations and radiolabeling with technetium-99m.
Results: mAb-D2 is an IgG1 with affinity constant of 7.2 × 109M-1 which can recognize CEA in tumor cells. Radiolabeling showed that 99mTc-HYNIC-mAb-D2 complex is stable, immunoradioactive, and has a desirable biodistribution.
Conclusion: In this study, we gained a new radiopharmaceutical that may be a good candidate for radioimmunoscintigraphy.
Materials and Methods: This research was done in three parts: preparation of hybridoma cell against colon cancer cell line (HT29), production of monoclonal antibody, determination of its characterizations and radiolabeling with technetium-99m.
Results: mAb-D2 is an IgG1 with affinity constant of 7.2 × 109M-1 which can recognize CEA in tumor cells. Radiolabeling showed that 99mTc-HYNIC-mAb-D2 complex is stable, immunoradioactive, and has a desirable biodistribution.
Conclusion: In this study, we gained a new radiopharmaceutical that may be a good candidate for radioimmunoscintigraphy.
Keywords: Monoclonal antibody, Radiopharmaceutical, Technetium-99m, Radioimmunoscintigraphy, Colon cancer
Type of Study: Research(Original) |
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
